In colon cancers, studies reported that the up-regulated expression of AKR1B10, AKR1C1, AKR1C2 and AKR1C3 contributed to chemotherapeutic drug resistance indirectly, by reducing oxidative stress generated by these chemotherapeutic agents (Deng et al., 2004). Here, AKR1C2 is linked to colonic neoplasm.